

Stringent patient selection improves outcomes in systemic light-chain amyloidosis after autologous stem cell transplantation in the upfront and relapsed setting

Christopher P. Venner,^{1,2} Julian D. Gillmore,¹ Sajitha Sachchithanatham,¹ Shameem Mahmood,¹ Thirusha Lane,¹ Darren Foard,¹ Murielle Roussel,³ Lisa Rannigan,¹ Simon DJ Gibbs,^{1,4} Jennifer H Pinney,¹ Carol J. Whelan,¹ Helen J. Lachmann,¹ Philip N. Hawkins,¹ and Ashutosh D. Wechalekar¹

¹National Amyloidosis Centre, University College London Medical School, UK; ²Cross Cancer Institute, University of Alberta, Edmonton, Canada; ³Hématologie Clinique, CHU Purpan, Toulouse, France; and ⁴Central Manchester University Hospital, Department of Clinical Haematology, Manchester, UK

Correspondence: a.wechalekar@ucl.ac.uk
doi:10.3324/haematol.2014.108191

Table 1: Criteria used to guide risk-stratification of patients pre-ASCT*

- > 2 organ involvement
- ECOG > 1
- eGFR \leq 45mL/min
- Symptomatic cardiac involvement
- HS troponin T \geq 0.06 ng/mL
- Autonomic neuropathy
- Symptomatic gastrointestinal involvement

*Criteria not used as absolute contraindications for transplant but rather to guide decision-making process.

Supplementary Table 2: Characteristics of pre-ASCT treatment regimens for patients undergoing transplantation in the relapsed setting

Pre-ASCT line of therapy (n)	Bortezomib based (%)	Thalidomide based (%)	Lenalidomide based (%)	Alkylator based (%)	VAD (%)	Other (%)
1 (57)	2	44	2	18	28	7
2 (39)	21	33	3	28	3	13
3 (17)	24	41	0	18	0	18
4 (2)	50	0	0	50	0	0
5 (1)	0	100	0	0	0	0
6 (1)	0	0	100	0	0	0